The relation between borderline intellectual capacity and neurodevelopmental disorders;Relación entre capacidad de inteligencia límite y trastornos del neurodesarrollo

Revista de Neurologia

Volumn 44, Issue 12, 2007, Pages 739-744

  Artigas Pallarés, Josep ^a,b,c   Rigau Ratera, E ^a,b   Garcia Nonell C ^b  

^a HOSPITAL DE SABADELL   (Spain)

^b Centre Medic Psyncron   (Spain)

^c Associació Catalana Nabiu   (Spain)

Author keywords

Attention deficit hyperactivity disorder; Autism; Borderline intellectual capacity; Fragile X syndrome; Mental retardation; Non verbal learning disorder; Pervasive developmental disorders

Indexed keywords

ALCOHOL;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BORDERLINE INTELLECTUAL CAPACITY; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; EARLY DIAGNOSIS; HEALTH SURVEY; HUMAN; INTELLECTUAL IMPAIRMENT; INTELLIGENCE QUOTIENT; LEARNING DISORDER; MAJOR CLINICAL STUDY; PRENATAL EXPOSURE; PREVALENCE; SCHOOL CHILD; BEHAVIOR DISORDER; CHILD; INTELLIGENCE; INTELLIGENCE TEST; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD BEHAVIOR DISORDERS; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; HUMANS; INTELLIGENCE; INTELLIGENCE TESTS; LEARNING DISORDERS; NEUROPSYCHOLOGICAL TESTS;

EID: 34948892737     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4412.2006434     Document Type: Article

References (46)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4 ed. revised). Washington: APA; 2000.
2. Gillberg C, Svenson B, Carlstrom G, Waldenstrom E, Rasmussen P. Mental retardation in Swedish urban children: some epidemiological considerations. Appl Res Ment Retard 1983; 4: 207-18.
3. Von Wendt L, Rantakallio P. Mild mental retardation in northern Finland. Ups J Med Sci Suppl 1987; 44: 47-51.
4. Hassiotis A, Ukoumunne O, Tyrer P, Piachaud J, Gilvarry C, Harvey K, et al. Prevalence and characteristics of patients with severe mental illness and 'borderline' intellectual functioning. Report from the UK700 randomised controlled trial of case management. Br J Psychiatry 1999; 175: 135-40.
5. Puerta IC, Martínez J, Pineda DA. Prevalencia del retardo mental en adolescentes con trastorno disocial de la conducta. Rev Neurol 2002; 35: 1014-8.
6. Ninivaggi FJ. Borderline intellectual functioning in children and adolescents: reexamining an underrecognized yet prevalent clinical comorbidity. Conn Med 2001; 65: 7-11.
7. Masi G, Marcheschi M, Pfanner P. Adolescents with borderline intellectual functioning: psychopathological risk. Adolescence 1998; 33: 415-24.
8. Mani S, McDermott S, Valtorta M. MENTOR: a Bayesian model for prediction of mental retardation in newborns. Res Dev Disabil 1997; 18: 303-18.
9. Futagi Y, Suzuki Y, Goto M. Clinical significance of plantar grasp response in infants. Pediatr Neurol 1999; 20: 111-5.
10. Futagi Y, Suzuki Y, Toribe Y, Kato T. Neurologic outcomes of infants with tremor within the first year of life. Pediatr Neurol 1999; 21: 557-61.
11. Futagi Y, Otani K, Goto M. Prognosis of infants with ankle clonus within the first year of life. Brain Dev 1997; 19: 50-4.
12. Bowen JR, Gibson FL, Leslie GI, Arnold JD, Ma PJ, Starte DR. Predictive value of the Griffiths assessment in extremely low birthweight infants. J Paediatr Child Health 1996; 32: 25-30.
13. Claeys V, Calame A, Fawer CL, Ducret S, Arrazola L, Jaunin L. Neurodevelopmental abnormalities in preschool children with high perinatal risk. Prognostic value and consequences on education at 8 years of age. Helv Paediatr Acta 1984; 39: 293-306.
14. Zetlin A, Murtaugh M. Whatever happened to those with 'borderline' IQs? Am J Ment Retard 1990; 94: 463-9.
15. Van Bellinghen M, De Troch C. Risperidone in the treatment of behavioral disturbances in children and adolescents with 'borderline' intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 2001; 11: 5-13.
16. Buitelaar JK, Van der Gaag RJ, Cohen-Kettenis P, Melman CT. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 2001; 62: 239-48.
17. Aman MG, Kern RA, Osborne P, Tumuluru R, Rojahn J, Del Medico V. Fenfluramine and methylphenidate in children with mental retardation and 'borderline' IQ: clinical effects. Am J Ment Retard 1997; 101: 521-34.
18. Achenbach, TM. Child Behavior Checklist for children and adolescents aged 6-18. Burlington, VT: ASEBA; 2001.
19. Behavior Rating Inventory of Executive Function (BRIEF). Lutz: PAR Psychological Assessment Resources; 1996.
20. Farré A, Narbona J. EDAH, escala para la evaluación del trastorno por déficit de atención con hiperactividad. 4 ed. Madrid: TEA; 2001.
21. Swanson JM. The SNAP-IV. Parent Rating Scale. Irvine: University of California; 1995.
22. Assessment Data Manager Program (ADM). CBCL, YSR, TRF, ASR, ABCL, YASR, YABCL, SCICA. CBCL/2-3, CBCL/11/2-5 & C-TRF. Burlington: ASEBA; 2003.
23. Mandes E, Massimino C, Mantis C. A comparison of 'borderline' and mild mental retardates assessed on the memory for designs and the WAIS-R. J Clin Psychol 1991; 47: 562-7.
24. Hassiotis A, Ukoumunne OC, Byford S, Tyrer P, Harvey K, Piachaud J, et al. Intellectual functioning and outcome of patients with severe psychotic illness randomised to intensive case management. Report from the UK700 trial. Br J Psychiatry 2001; 178: 166-71.
25. Demb HB, Brier N, Huron R, Tomor E. The Adolescent Behavior Checklist: normative data and sensitivity and specificity of a screening tool for diagnosable psychiatric disorders in adolescents with mental retardation and other development disabilities. Res Dev Disabil 1994; 15: 151-65.
26. Antshel KM, Phillips MH, Gordon M, Barkley R, Faraone SV. Is ADHD a valid disorder in children with intellectual delays? Clin Psychol Rev 2006; 26: 555-72.
27. Biederman J, Monuteaux MC, Kendrick E, Klein KL, Faraone SV. The CBCL as a screen for psychiatric comorbidity in paediatric patients with ADHD. Arch Dis Child 2005; 90: 1010-5.
28. Welch-Carre E. The neurodevelopmental consequences of prenatal alcohol exposure. Adv Neonatal Care 2005; 5: 217-29.
29. Tassone F, Hagerman RJ, Taylor AK, Mills JB, Harris SW, Gane LW, et al. Clinical involvement and protein expression in individuals with the FMR1 premutation. Am J Med Genet 2000; 91: 144-52.
30. Brun C, Artigas J, Ramírez A, Lorente I, Gabau E, Milà M. Manifestaciones clínicas de la premutación frágil X en niños. Rev Neurol 2001; 33: 263.
31. Rourke BP. Syndrome of nonverbal learning disabilities. Neurodevelopmental manifestations. New York: Guildford Press; 2002.
32. Rigau-Ratera E, García-Nonell C, Artigas-Pallarés J. Características del trastorno de aprendizaje no verbal. Rev Neurol 2004; 38 (Supl 1): S33-8.
33. Fuster JM. The cortical substrate of general intelligence. Cortex 2005; 41: 228-9.
34. Kadesjo B, Gillberg C. The comorbidity of ADHD in the general population of Swedish school-age children. J Child Psychol Psychiatr 2001; 42: 487-92.
35. Thurstone LL. Primary mental abilities. Chicago: University of Chicago Press; 1938.
36. Spearman C. The abilities of man: their nature and measurement. New York: Macmillan; 1927.
37. Cattell RB. Theory of fluid and crystallized intelligence: a critical experiment. J Educ Psychol 1963; 54: 1-22.
38. Artigas-Pallarés J. Perfiles cognitivos de la inteligencia limite. Fronteras del retardo mental. Rev Neurol 2003; 36 (Supl 1): S161-7.
39. Gray JR, Chabris CF, Braver TS. Neural mechanisms of general fluid intelligence. Nat Neurosci 2003; 6: 316-22.
40. Baddeley AD, Hitch GJ. Working memory. In Bower G, ed. The psychology of learning and motivation. Vol 7. New York: Academic Press; 1974. p. 47-89.
41. Baddeley AD. Working memory. Science 1992; 255: 556-9.
42. Barkley RA. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. 3 ed. New York: Guilford Press; 2006.
43. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257-69.
44. Blasi G, Mattay VS, Bertolino A, Elvevag B, Callicott JH, Das S, et al. Effect of catechol-O-methyltransferase val158met genotype on attentional control. J Neurosci 2005; 25: 5038-45.
45. Fan J, Fossella J, Sommer T, Wu Y, Posner MI. Mapping the genetic variation of executive attention onto brain activity. Proc Natl Acad Sci U S A 2003; 10; 100: 7406-11.
46. Salthouse TA, Atkinson TM, Berish DE. Executive functioning as a potential mediator of age-related cognitive decline in normal adults. J Exp Psychol Gen 2003; 132: 566-94.